Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts

Pharmacology and Therapeutics

Volumn 96, Issue 1, 2002, Pages 45-66

  Gurvich, Nadia ^a   Klein, Peter S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bipolar disorder; GSK 3; Histone deacetylase; Inositol; Lithium; Valproic acid

Indexed keywords

4 AMINOBUTYRIC ACID; ARACHIDONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; ENZYME INHIBITOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE; INOSITOL; INOSITOL MONOPHOSPHATASE; LITHIUM; MARCKS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATASE; PHOSPHOGLUCOMUTASE; PROTEIN BCL 2; PROTEIN KINASE C; SODIUM CHANNEL; SODIUM ION; TAU PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VALPROIC ACID; WNT PROTEIN;

ARTICLE; BIPOLAR DISORDER; CLINICAL MEDICINE; CLINICAL TRIAL; DEVELOPMENT; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE IDENTIFICATION; HEMATOPOIESIS; HUMAN; MOLECULAR BIOLOGY; NERVE CELL; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TERATOGENICITY;

EID: 0036810240     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00299-1     Document Type: Review

References (293)

1. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:1997;3797-3804.
2. Acharya J.K., Labarca P., Delgado R., Jalink K., Zuker C.S. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron. 20:1998;1219-1229.
3. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 22:2000;62-65.
4. Albus H., Williamson R. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia. 39:1998;124-139.
5. Alland L., Muhle R., Hou H. Jr., Potes J., Chin L., Schreiber-Agus N., DePinho R.A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 387:1997;49-55.
6. Allison J.H., Boshans R.L., Hallcher L.M., Packman P.M., Sherman W.R. The effects of lithium on myo-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum of the rat. J Neurochem. 34:1980;456-458.
7. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 453:1999;260-264.
8. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., Richardson J.A., Hill J.A., Olson E.N. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 99:2002;907-912.
9. Asghari V., Wang J.F., Reiach J.S., Young L.T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res. 58:1998;95-102.
10. Atack J.R., Cook S.M., Watt A.P., Fletcher S.R., Ragan C.I. In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J Neurochem. 60:1993;652-658.
11. Ault K.T., Durmwicz G., Galione A., Harger P.L., Busa W.B. Modulation of Xenopus embryo mesoderm-specific gene expression and dorsoanterior patterning by receptors that activate the phosphatidylinositol cycle signal transduction pathway. Development. 122:1996;2033-2041.
12. Baldessarini R., Vogt M. Release of 3H-dopamine and analogous monoamines from rat striatal tissue. Cell Mol Neurobiol. 8:1988;205-216.
13. Baraban J. Towards a crystal-clear view of lithium's site of action. Proc Natl Acad Sci USA. 91:1994;5738-5739.
14. Barnes G.L. Jr., Mariani B.D., Tuan R.S. Valproic acid-induced somite teratogenesis in the chick embryo: relationship with Pax-1 gene expression. Teratology. 54:1996;93-102.
15. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 275:1997;1930-1934.
16. Bennett G.S., Laskowska D., DiLullo C. Lithium chloride inhibits the phosphorylation of newly synthesized neurofilament protein, NF-M, in cultured chick sensory neurons. J Neurochem. 57:1991;120-129.
17. Berridge M.J., Irvine R.F. Inositol phosphates and cell signalling. Nature. 341:1989;197-205.
18. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 59:1989;411-419.
19. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3β facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 275:2000;7583-7590.
20. Billin A.N., Thirlwell H., Ayer D.E. β-Catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol. 20:2000;6882-6890.
21. Boggs D.R., Joyce R.A. The hematopoietic effects of lithium. Semin Hematol. 20:1983;129-138.
22. Bojic U., Ehlers K., Ellerbeck U., Bacon C.L., O'Driscoll E., O'Connell C., Berezin V., Kawa A., Lepekhin E., Bock E., Regan C.M., Nau H. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. Eur J Pharmacol. 354:1998;289-299.
23. Bone R., Frank L., Springer J.P., Atack J.R. Structural studies of metal binding by inositol monophosphatase: evidence for two-metal ion catalysis. Biochemistry. 33:1994;9468-9476.
24. Bosch F., Gomez-Foix A.M., Arino J., Guinovart J.J. Effects of lithium ions on glycogen synthase and phosphorylase in rat hepatocytes. J Biol Chem. 261:1986;16927-16931.
25. Bosetti F., Seemann R., Bell J.M., Zahorchak R., Friedman E., Rapoport S.I., Manickam P. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res Bull. 57:2002;205-209.
26. Bowden C.L., McElroy S.L. History of the development of valproate for treatment of bipolar disorder. J Clin Psychiatry. 56(suppl. 3):1995;3-5.
27. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G., Garza-Trevino E.S., Risch S.C., Goodnick P.J., Morris D.D. for the Depakote Mania Study Group Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 271:1994;918-924. Erratum: JAMA 271, 1830 (1994).
28. Boyle W.J., Smeal T., Defize L.H.K., Woodgett J.R., Karin M., Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell. 64:1991;573-584.
29. Brantjes H., Roose J., van De Wetering M., Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res. 29:2001;1410-1419.
30. 2+-valproate in cultured cerebellar neurons. Funct Neurol. 10:1995;121-130.
31. Burden S.J. Wnts as retrograde signals for axon and growth cone differentiation. Cell. 100:2000;495-497.
32. Burstein D.E., Seeley P.J., Greene L.A. Lithium ion inhibits nerve growth factor-induced neurite outgrowth and phosphorylation of nerve growth factor-modulated microtubule-associated proteins. J Cell Biol. 101:1985;862-870.
33. Busa W.B., Gimlich R.L. Lithium-induced teratogenesis in frog embryos prevented by a polyphosphoinositide cycle intermediate or a diacylglycerol analog. Dev Biol. 132:1989;315-324.
34. Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust. 2:1949;349-352.
35. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 11:1997;3286-3305.
36. Centeno F., Mora A., Fuentes J.M., Soler G., Claro E. Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport. 9:1998;4199-4203.
37. Chang M.C., Grange E., Rabin O., Bell J.M., Allen D.D., Rapoport S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett. 220:1996;171-174.
38. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem. 77:2001;796-803.
39. Chen G., Manji H.K., Hawver D.B., Wright C.B., Potter W.Z. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem. 63:1994;2361-2364.
40. Chen G., Yuan P., Hawver D.B., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
41. Chen G., Yuan P.X., Jiang Y.M., Huang L.D., Manji H.K. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem. 70:1998;1768-1771.
42. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 72:1999;879-882.
43. Chen R.H., Ding W.V., McCormick F. Wnt signaling to β-catenin involves two interactive components. Glycogen synthase kinase-3β inhibition and activation of protein kinase C. J Biol Chem. 275:2000;17894-17899.
44. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 274:1999;6039-6042.
45. 1. Am J Physiol. 275:1998;E272-E277.
46. Cheng K., Creacy S., Larner J. 'Insulin-like' effects of lithium ion on isolated rat adipocytes. I. Stimulation of glycogenesis beyond glucose transport. Mol Cell Biochem. 56:1983;177-182.
47. Choi W.S., Sung C.K. Effects of lithium and insulin on glycogen synthesis in L6 myocytes: additive effects on inactivation of glycogen synthase kinase-3. Biochim Biophys Acta. 1475:2000;225-230.
48. Cinatl J. Jr., Cinatl J., Scholz M., Driever P.H., Henrich D., Kabickova H., Vogel J.U., Doerr H.W., Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 7:1996;766-773.
49. Coghlan M.P., Culbert A.A., Cross D.A.E., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 7:2000;793-803.
50. Cohen P., Yellowlees D., Aitken A., Donella-Deana A., Hemmings B.A., Parker P.J. Separation and characterisation of glycogen synthase kinase 3, glycogen synthase kinase 4 and glycogen synthase kinase 5 from rabbit skeletal muscle. Eur J Biochem. 124:1982;21-35.
51. Collins A.F., Dover G.J., Luban N.L. Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy. Blood. 84:1994;1690-1691.
52. Cook D., Fry M.J., Hughes K., Sumathipala R., Woodgett J.R., Dale T.C. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J. 15:1996;4526-4536.
53. Coppen A. Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry. 61:2000;52-56.
54. Covington E.C. Anticonvulsants for neuropathic pain and detoxification. Cleve Clin J Med. 65:1998;SI21-SI29. discussion SI45-SI47.
55. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 184:2000;1-16.
56. Cross D., Alessi D., Cohen P., Andjelkovich M., Hemmings B. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:1995;785-789.
57. Cross D.A., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., Reith A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem. 77:2001;94-102.
58. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3β activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem. 275:2000;34266-34271.
59. Culbert A.A., Brown M.J., Frame S., Hagen T., Cross D.A., Bax B., Reith A.D. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett. 507:2001;288-294.
60. Czech M.P. Signal transmission by the insulin-like growth factors. Cell. 59:1989;235-238.
61. Davies J.A., Garrod D.R. Induction of early stages of kidney differentiation by lithium ions. Dev Biol. 167:1995;50-60.
62. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 351:2000;95-105.
63. Dawson D.A. Additive incidence of developmental malformation for Xenopus embryos exposed to a mixture of ten aliphatic carboxylic acids. Teratology. 44:1991;531-546.
64. de Groot R.P., Auwerx J., Bourouis M., Sassone-Corsi P. Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene. 7:1993;841-847.
65. De Leon O.A. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry. 9:2001;209-222.
66. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
67. Dixon J.F., Hokin L.E. Lithium stimulates accumulation of second-messenger inositol 1,4,5-trisphosphate and other inositol phosphates in mouse pancreatic minilobules without inositol supplementation. Biochem J. 304:1994;251-258.
68. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc Natl Acad Sci USA. 94:1997;4757-4760.
69. Dixon J.F., Hokin L.E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA. 95:1998;8363-8368.
70. Dixon J.F., Lee C.H., Los G.V., Hokin L.E. Lithium enhances accumulation of [3H]inositol radioactivity and mass of second messenger inositol 1,4,5-trisphosphate in monkey cerebral cortex slices. J Neurochem. 59:1992;2332-2335.
71. Dixon J.F., Los G.V., Hokin L.E. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc Natl Acad Sci USA. 91:1994;8358-8362.
72. Dominguez I., Itoh K., Sokol S.Y. Role of glycogen synthase kinase 3β as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci USA. 92:1995;8498-8502.
73. Driever P.H., Knupfer M.M., Cinatl J., Wolff J.E. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr. 211:1999;323-328.
74. Eickholt B.J., Walsh F.S., Doherty P. An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J Cell Biol. 157:2002;211-217.
75. Ekbom K., Hardebo J.E. Cluster headache: aetiology, diagnosis and management. Drug. 62:2002;61-69.
76. El-Mallakh R.S., Jefferson J.W. Prethymoleptic use of lithium. Am J Psychiatry. 156:1999;129.
77. Emily-Fenouil F., Ghiglione C., Lhomond G., Lepage T., Gache C. GSK3β/shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo. Development. 125:1998;2489-2498.
78. Emrich H.M., von Zerssen D., Kissling W., Moller H.J., Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr. 229:1980;1-16.
79. Fauroux C.M., Freeman S. Inhibitors of inositol monophosphatase. J Enzyme Inhib. 14:1999;97-108.
80. Felber W. Lithium prevention of depression 100 years ago - an ingenious misconception. (German). Fortschr Neurol Psychiatr. 55:1987;141-144.
81. Fredieu J.R., Cui Y., Maier D., Danilchik M.V., Christian J.L. Xwnt-8 and lithium can act upon either dorsal mesodermal or neurectodermal cells to cause a loss of forebrain in Xenopus embryos. Dev Biol. 186:1997;100-114.
82. Frey H.H., Loscher W. Di-n-propylacetic acid-profile of anticonvulsant activity in mice. Arzneimittelforschung. 26:1976;299-301.
83. Friedman E., Hoau Yan W., Levinson D., Connell T.A., Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 33:1993;520-525.
84. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl). 158:2001;100-106.
85. Furnsinn C., Noe C., Herdlicka R., Roden M., Nowotny P., Leighton B., Waldhausl W. More marked stimulation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol. 273:1997;E514-E520.
86. Gallicchio V.S. Lithium and hematopoietic toxicity. III. In vivo recovery of hematopoiesis following single-dose administration of cyclophosphamide. Acta Haematol. 79:1988;192-197.
87. Garcia-Perez J., Avila J., Diaz-Nido J. Lithium induces morphological differentiation of mouse neuroblastoma cells. J Neurosci Res. 57:1999;261-270.
88. Gilman A.G., Rall T.W., Nies A.S., Taylor P. The Pharmacological Basis of Therapeutics. 1999;Pergamon Press, New York.
89. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. 1990;Oxford University Press, New York.
90. Goold R.G., Owen R., Gordon-Weeks P.R. Glycogen synthase kinase 3β phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci. 112:1999;3373-3384.
91. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:2001;6969-6978.
92. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol. 65:2001;391-426.
93. Grimm V., Gottesfeld Z., Wassermann I., Samuel D. The level of GABA in the brain and locomotor behavior. Pharmacol Biochem Behav. 3:1975;573-578.
94. Hahn C.G., Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 1:1999;81-86.
95. Hall A.C., Lucas F.R., Salinas P.C. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell. 100:2000;525-535.
96. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem. 255:1980;10896-10901.
97. Hamilton F.S., Wheeler G.N., Hoppler S. Difference in XTcf-3 dependency accounts for change in response to β-catenin-mediated Wnt signalling in Xenopus blastula. Development. 128:2001;2063-2073.
98. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., Molkentin J.D., Alessandrini A., Woodgett J., Hajjar R., Michael A., Force T. Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 151:2000;117-130.
99. Harwood A.J., Plyte S.E., Woodgett J., Strutt H., Kay R.R. Glycogen synthase kinase 3 regulates cell fate in Dictyostelium. Cell. 80:1995;139-148.
100. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem. 80:2002;589-597.
101. Hassel M., Bieller A. Stepwise transfer from high to low lithium concentrations increases the head-forming potential in Hydra vulgaris and possibly activates the PI cycle. Dev Biol. 177:1996;439-448.
102. Hassig C.A., Fleischer T.C., Billin A.N., Schreiber S.L., Ayer D.E. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell. 89:1997;341-347.
103. Haugaard E.S., Mickel R.A., Haugaard N. Actions of lithium ions and insulin on glucose utilization, glycogen synthesis and glycogen synthase in the isolated rat diaphragm. Biochem Pharmacol. 23:1974;1675-1685.
104. He X., Saint-Jeannet J.-P., Woodgett J.R., Varmus H.E., Dawid I.B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature. 374:1995;617-622.
105. Hedgepeth C., Conrad L., Zhang Z., Huang H., Lee V., Klein P. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol. 185:1997;82-91.
106. Hedgepeth C.M., Deardorff M.A., Rankin K., Klein P.S. Regulation of glycogen synthase kinase 3β and downstream Wnt signaling by axin. Mol Cell Biol. 19:1999;7147-7157.
107. Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M., Laherty C.D., Torchia J., Yang W.M., Brard G., Ngo S.D., Davie J.R., Seto E., Eisenman R.N., Rose D.W., Glass C.K., Rosenfeld M.G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 387:1997;43-48.
108. Hetman M., Cavanaugh J.E., Kimelman D., Xia Z. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal. J Neurosci. 20:2000;2567-2574.
109. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 406:2000;86-90.
110. Honchar M.P., Ackermann K.E., Sherman W.R. Chronically administered lithium alters neither myo-inositol monophosphatase activity nor phosphoinositide levels in rat brain. J Neurochem. 53:1989;590-594.
111. Hong M., Chen D.C., Klein P.S., Lee V.M.-Y. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem. 272:1997;25326-25332.
112. Hori C., Oka T. Induction by lithium ion of multiplication of mouse mammary epithelium in culture. Proc Natl Acad Sci USA. 76:1979;2823-2827.
113. Hua L.V., Green M., Wong A., Warsh J.J., Li P.P. Tetraspan protein CD151: a common target of mood stabilizing drugs? Neuropsychopharmacology. 25:2001;729-736.
114. Inouye M., Yamamura H., Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J Radiat Res (Tokyo). 36:1995;203-208.
115. Jenkinson S., Patel N., Nahorski S.R., Challiss R.A. Comparative effects of lithium on the phosphoinositide cycle in rat cerebral cortex, hippocampus, and striatum. J Neurochem. 61:1993;1082-1090.
116. Jerka-Dziadosz M., Frankel J. The effects of lithium chloride on pattern formation in Tetrahymena thermophila. Dev Biol. 171:1995;497-506.
117. Jia J., Amanai K., Wang G., Tang J., Wang B., Jiang J. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature. 416:2002;548-552.
118. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem Int. 37:2000;103-110.
119. Johnson F.N., Amdisen A. The first era of lithium in medicine. An historical note. Pharmacopsychiatria. 16:1983;61-63.
120. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 4:1999;117-128.
121. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem Pharmacol. 47:1994;429-441.
122. Joyce R.A., Chervenick P.A. Lithium effects on granulopoiesis in mice following cytotoxic chemotherapy. Adv Exp Med Biol. 127:1980;145-154.
123. Kadosh D., Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell. 89:1997;365-371.
124. Kao K.R., Masui Y., Elinson R.P. Lithium-induced respecification of pattern in Xenopus laevis embryos. Nature. 322:1986;371-373.
125. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 93:1996;8455-8459.
126. Knoepfler P.S., Eisenman R.N. Sin meets NuRD and other tails of repression. Cell. 99:1999;447-450.
127. Kofron M., Klein P., Zhang F., Houston D.W., Schaible K., Wylie C., Heasman J. The role of maternal axin in patterning the Xenopus embryo. Dev Biol. 237:2001;183-201.
128. Korycka A., Robak T. The effect of lithium chloride on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic leukaemic blasts (CFU-L) in the cultures in vitro. Arch Immunol Ther Exp. 39:1991;495-500.
129. Korycka A., Robak T. The effect of lithium on haematopoiesis of patients with acute myeloid leukaemia. Arch Immunol Ther Exp. 39:1991;501-509.
130. Kramer O.H., Gottlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 12:2001;294-300.
131. Kume S., Muto A., Inoue T., Suga K., Okano H., Mikoshiba K. Role of inositol 1,4,5-trisphosphate receptor in ventral signaling in Xenopus embryos. Science. 278:1997;1940-1943.
132. Laherty C.D., Yang W.M., Sun J.M., Davie J.R., Seto E., Eisenman R.N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 89:1997;349-356.
133. Lambert P.A., Cavaz G., Borselli S., Carbel S. Action neuropsychotrope d'un nouvel anti-epileptique: le depamide. Ann Med Pyschol (Paris). 1:1966;707-710.
134. Lampen A., Siehler S., Ellerbeck U., Gottlicher M., Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARδ). Toxicol Appl Pharmacol. 160:1999;238-249.
135. Larsson O.M., Gram L., Schousboe I., Schousboe A. Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Neuropharmacology. 25:1986;617-625.
136. Lawrence J.C. Jr., Roach P.J. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 46:1997;541-547.
137. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 276:2001;251-260.
138. Lee V.M.-Y. Disruption of the cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol. 5:1995;663-668.
139. Lee V.M.-Y., Trojanowski J.Q. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron. 24:1999;507-510.
140. Lenox R.H., Watson D.G. Lithium and the brain: a psychopharmological strategy to a molecular basis for manic depressive illness. Clin Chem. 40:1994;309-314.
141. Lenox R.H., Watson D.G., Patel J., Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570:1992;333-340.
142. Lenox R.H., McNamara R.K., Papke R.L., Manji H.K. Neurobiology of lithium: an update. J Clin Psychiatry. 59:1998;37-47.
143. Lenox R.H., Gould T.D., Manji H.K. Endophenotypes in bipolar disorder. Am J Med Genet. 114:2002;391-406.
144. Leost M., Schultz C., Link A., Wu Y.Z., Biernat J., Mandelkow E.M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W., Gussio R., Senderowicz A.M., Sausville E.A., Kunick C., Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3β & cyclin-dependent kinase 5/p25. Eur J Biochem. 267:2001;5983-5994.
145. Liakopoulou E., Blau C.A., Li Q., Josephson B., Wolf J.A., Fournarakis B., Raisys V., Dover G., Papayannopoulou T., Stamatoyannopoulos G. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood. 86:1995;3227-3235.
146. Liang P., Bauer D., Averboukh L., Warthoe P., Rohrwild M., Muller H., Strauss M., Pardee A.B. Analysis of altered gene expression by differential display. Methods Enzymol. 254:1995;304-321.
147. Livingston B.T., Wilt F.H. Lithium evokes expression of vegetal-specific molecules in the animal blastomeres of sea urchin embryos. Proc Natl Acad Sci USA. 86:1989;3669-3673.
148. Logan C.Y., Miller J.R., Ferkowicz M.J., McClay D.R. Nuclear β-catenin is required to specify vegetal cell fates in the sea urchin embryo. Development. 126:1999;345-357.
149. Lopez-Coronado J.M., Belles J.M., Lesage F., Serrano R., Rodriguez P.L. A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3′-phosphoadenosine 5′-phosphate phosphatase and inositol-polyphosphate 1-phosphatase. J Biol Chem. 274:1999;16034-16039.
150. Loscher W. Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. J Neurochem. 36:1981;1521-1527.
151. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol. 30:1981;1364-1366.
152. Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
153. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 58:1999;31-59.
154. Loscher W., Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia. 21:1980;611-615.
155. Lovestone S., Reynolds C.H., Latimer D., Davis D., Anderton B., Gallo J., Hanger D., Mulot S., Marquardt B., Stabel S., Woodgett J.R., Miller C. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Bio. 4:1994;1077-1086.
156. Lovestone S., Davis D.R., Webster M.T., Kaech S., Brion J.P., Matus A., Anderton B.H. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry. 45:1999;995-1003.
157. Lucas F.R., Salinas P.C. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol. 192:1997;31-44.
158. Lucas F.R., Goold R.G., Gordon-Weeks P.R., Salinas P.C. Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci. 111:1998;1351-1361.
159. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation, and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20:2001;27-39.
160. Maeda Y. Influence of ionic conditions on cell differentiation and morphogenesis of the cellular slime molds. Dev Growth Differ. 12:1970;217-227.
161. Maggirwar S.B., Tong N., Ramirez S., Gelbard H.A., Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3β contributes to Tat-mediated neurotoxicity. J Neurochem. 73:1999;578-586.
162. Maitre M., Ossola L., Mandel P. In vitro studies into the effect of inhibition of rat brain succinic semialdehyde dehydrogenase on GABA synthesis and degradation. FEBS Lett. 72:1976;53-57.
163. Mandelkow E.-M., Mandelkow E. Tau as a marker for Alzheimer's disease. Trends Biochem Sci. 18:1993;480-483.
164. Manji H.K., Lenox R.H. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry. 46:1999;1328-1351.
165. Manji H.K., Etcheberrigaray R., Chen G., Olds J.L. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem. 61:1993;2303-2310.
166. Manji H., Potter W., Lenox R. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry. 52:1995;531-543.
167. Manji H.K., Chen G., Hsiao J.K., Risby E.D., Masana M.I., Potter W.Z. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry. 57:1996;34-46. discussion 47-48.
168. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry. 60:1999;27-39. discussion 40-1, 113-116.
169. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry. 46:1999;929-940.
170. Marianna P., Kollia P., Akel S., Papassotiriou Y., Stamoulakatou A., Loukopoulos D. Valproic acid, trichostatin and their combination with hemin preferentially enhance gamma-globin gene expression in human erythroid liquid cultures. Haematologica. 86:2001;700-705.
171. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging. 16:1995;187-198.
172. Martin M.L., Regan C.M. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 554:1991;223-228.
173. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 45:2002;1292-1299.
174. Maslanski J.A., Leshko L., Busa W.B. Lithium-sensitive production of inositol phosphates during amphibian embryonic mesoderm induction. Science. 256:1992;243-245.
175. Masuda C.A., Xavier M.A., Mattos K.A., Galina A., Montero-Lomeli M. Phosphoglucomutase is an in vivo lithium target in yeast. J Biol Chem. 276:2001;37794-37801.
176. Meijer L., Thunnissen A.M., White A.W., Garnier M., Nikolic M., Tsai L.H., Walter J., Cleverley K.E., Salinas P.C., Wu Y.Z., Biernat J., Mandelkow E.M., Kim S.H., Pettit G.R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol. 7:2000;51-63.
177. Meunier H., Carraz G., Meunier Y. Proprietes pharmacodynamiques de l'acide n-dipropylacetique. Therapie. 18:1963;435-438.
178. Miller J.R., McClay D.R. Changes in the pattern of adherens junction-associated β-catenin accompany morphogenesis in the sea urchin embryo. Dev Biol. 192:1997;310-322.
179. 2+ pathways. Oncogene. 18:1999;7860-7872.
180. Miyamoto R., Sugiura R., Kamitani S., Yada T., Lu Y., Sio S.O., Asakura M., Matsuhisa A., Shuntoh H., Kuno T. Tol1, a fission yeast phosphomonoesterase, is an in vivo target of lithium, and its deletion leads to sulfite auxotrophy. J Bacteriol. 182:2000;3619-3625.
181. Moore K.B., Schneider M.L., Vetter M.L. Posttranslational mechanisms control the timing of bHLH function and regulate retinal cell fate. Neuron. 34:2002;183-195.
182. +. Eur J Biochem. 266:1999;886-891.
183. Morgan T.H. The relation between normal and abnormal development of the embryo of the frog, as determined by the effect of lithium chloride in solution. Archiv Fur Entwickelungsmechanik. XVI:1902;691-716.
184. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., Sadoshima J. Glycogen synthase kinase 3β regulates GATA4 in cardiac myocytes. J Biol Chem. 276:2001;28586-28597.
185. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411:1997;183-188.
186. Murguia J.R., Belles J.M., Serrano R. A salt-sensitive 3′(2′),5′-bisphosphate nucleotidase involved in sulfate activation. Science. 267:1995;232-234.
187. Murray M., Greenberg M.L. Expression of yeast INM1 encoding inositol monophosphatase is regulated by inositol, carbon source and growth stage and is decreased by lithium and valproate. Mol Microbiol. 36:2000;651-661.
188. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 89:1997;373-380.
189. Nau H. Valproic acid-induced neural tube defects. Ciba Found Symp. 181:1994;144-152.
190. Nau H., Hauck R.S., Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol. 69:1991;310-321.
191. Ng H.H., Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci. 25:2000;121-126.
192. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport. 9:1998;2081-2084.
193. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA. 95:1998;2642-2647.
194. Oberemm A., Kirschbaum F. Valproic acid induced abnormal development of the central nervous system of three species of amphibians: implications for neural tube defects and alternative experimental systems. Teratog Carcinog Mutagen. 12:1992;251-262.
195. Odom A.R., Stahlberg A., Wente S.R., York J.D. A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science. 287:2000;2026-2029.
196. O'Donnell T., Rotzinger S., Nakashima T.T., Hanstock C.C., Ulrich M., Silverstone P.H. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res. 880:2000;84-91.
197. Orena S.J., Torchia A.J., Garofalo R.S. Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem. 275:2000;15765-15772.
198. Otvos L., Feiner L., Lang E., Szendrei G.I., Goedert M., Lee V.M.-Y. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 39:1994;669-673.
199. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem. 69:1997;2336-2344.
200. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 273:1998;19929-19932.
201. Pap M., Cooper G.M. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol Cell Biol. 22:2002;578-586.
202. Pazin M.J., Kadonaga J.T. What's up and down with histone deacetylation and transcription? Cell. 89:1997;325-328.
203. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol. 41:2001;789-813.
204. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 276:2001;36734-36741.
205. Phillips N.I., Fowler L.J. The effects of sodium valproate on gamma-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem Pharmacol. 31:1982;2257-2261.
206. Pierce S.B., Kimelman D. Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3. Development. 121:1995;755-765.
207. Plyte S.E., Hughes K., Nikolakaki E., Pulverer B.J., Woodgett J.R. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta. 1114:1992;147-162.
208. Polakis P. Wnt signaling and cancer. Genes Dev. 14:2000;1837-1851.
209. Pollack S.J., Knowles M.R., Atack J.R., Broughton H.B., Ragan C.I., Osborne S., McAllister G. Probing the role of metal ions in the mechanism of inositol monophosphatase by site-directed mutagenesis. Eur J Biochem. 217:1993;281-287.
210. Price L.H., Heninger G.R. Lithium in the treatment of mood disorders. N Engl J Med. 331:1994;591-598.
211. Price M.A., Kalderon D. Proteolysis of the hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell. 108:2002;823-835.
212. Ptashne K., Stockdale F.E., Conlon S. Initiation of DNA synthesis in mammary epithelium and mammary tumors by lithium ions. J Cell Physiol. 103:1980;41-46.
213. Quintero F.J., Garciadeblas B., Rodriguez-Navarro A. The SAL1 gene of Arabidopsis, encoding an enzyme with 3′(2′),5′-bisphosphate nucleotidase and inositol polyphosphate 1-phosphatase activities, increases salt tolerance in yeast. Plant Cell. 8:1996;529-537.
214. Ray W.J. Jr., Szymanki E.S., Ng L. The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta. 522:1978;434-442.
215. Regan C.M. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res. 347:1985;394-398.
216. Rhyu G.I., Ray W.J. Jr., Markley J.L. Multinuclear magnetic resonance studies of metal ion binding sites of phosphoglucomutase. Biochemistry. 24:1985;2536-2541.
217. Rice A.M., Sartorelli A.C. Inhibition of 20S and 26S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans retinoic acid. J Biol Chem. 276:2001;42722-42727.
218. Riggleman B., Schedl P., Weischaus E. Spatial expression of the Drosophila segment polarity gene armadillo is post-transcriptionally regulated by wingless. Cell. 63:1990;549-560.
219. Rintala J., Seemann R., Chandrasekaran K., Rosenberger T.A., Chang L., Contreras M.A., Rapoport S.I., Chang M.C. 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport. 10:1999;3887-3890.
220. Robert E., Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 2:1982;937.
221. Robinson W.A., Entringer M.A., Huber J., Gupta R. In vivo and in vitro effects of lithium on granulopoiesis in human neutropenic disorders. Adv Exp Med Biol. 127:1980;281-291.
222. Rodriguez-Gil J.E., Guinovart J.J., Bosch F. Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. Arch Biochem Biophys. 301:1993;411-415.
223. Rogatsky I., Waase C.L., Garabedian M.J. Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem. 273:1998;14315-14321.
224. Rogers C. Lithium: Part 1-History. Aust Nurses J. 19:1989;29.
225. Rogers I., Varmuza S. Epigenetic alterations brought about by lithium treatment disrupt mouse embryo development. Mol Reprod Dev. 45:1996;163-170.
226. Zeste-white3 by components of the wingless pathway in Drosophila cells and embryos. J Biol Chem. 274:1999;21790-21796.
227. Rundlett S.E., Carmen A.A., Suka N., Turner B.M., Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature. 392:1998;831-835.
228. Ryves W.J., Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 280:2001;720-725.
229. Salinas P.C. Wnt factors in axonal remodelling and synaptogenesis. Biochem Soc Symp. 65:1999;101-109.
230. Sands S.A., Guerra V., Morilak D.A. Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacology. 22:2000;27-35.
231. Saneyoshi T., Kume S., Amasaki Y., Mikoshiba K. The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature. 417:2002;295-299.
232. Sayas C.L., Moreno-Flores M.T., Avila J., Wandosell F. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. J Biol Chem. 274:1999;37046-37052.
233. Schou M. Lithium treatment at 52. J Affect Disord. 67:2001;21-32.
234. Selby R., Nisbet-Brown E., Basran R.K., Chang L., Olivieri N.F. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood. 90:1997;891-893.
235. Shaldubina A., Ju S., Vaden D.L., Ding D., Belmaker R.H., Greenberg M.L. Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase. Mol Psychiatry. 7:2002;174-180.
236. Shore D. The sir2 protein family: a novel deacetylase for gene silencing and more. Proc Natl Acad Sci USA. 97:2000;14030-14032.
237. Siegfried E., Perrimon N. Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays. 16:1994;395-404.
238. Siegfried E., Perkins L.A., Capaci T.M., Perrimon N. Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3. Nature. 345:1990;825-829.
239. Siegfried E., Chou T.B., Perrimon N. Wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate. Cell. 71:1992;1167-1179.
240. Siegfried E., Wilder E.L., Perrimon N. Components of wingless signalling in Drosophila. Nature. 367:1994;76-80.
241. Silberstein S.D. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 36:1996;547-555.
242. Smith D.G., Buffet M., Fenwick A.E., Haigh D., Ife R.J., Saunders M., Slingsby B.P., Stacey R., Ward R.W. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 11:2001;635-639.
243. Spiegelberg B.D., Xiong J.P., Smith J.J., Gu R.F., York J.D. Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3′-nucleotidase inhibited by inositol 1,4-bisphosphate. J Biol Chem. 274:1999;13619-13628.
244. Stachel S.E., Grunwald D.J., Myers P.Z. Lithium perturbation and goosecoid expression identify a dorsal specification pathway in the pregastrula zebrafish. Development. 117:1993;1261-1274.
245. Stambolic V., Ruel L., Woodgett J. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 6:1996;1664-1668.
246. Stoll A.L., Severus W.E. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harv Rev Psychiatry. 4:1996;77-89.
247. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:1998;599-606.
248. Summers S.A., Kao A.W., Kohn A.D., Backus G.S., Roth R.A., Pessin J.E., Birnbaum M.J. The role of glycogen synthase kinase 3β in insulin-stimulated glucose metabolism. J Biol Chem. 274:1999;17934-17940.
249. Szabo K.T. Teratogenic effect of lithium carbonate in the foetal mouse. Nature. 225:1970;73-75.
250. Tabata I., Schluter J., Gulve E.A., Holloszy J.O. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes. 43:1994;903-907.
251. Takahashi M., Yasutake K., Tomizawa K. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons. J Neurochem. 73:1999;2073-2083.
252. Takei K., Shin R.M., Inoue T., Kato K., Mikoshiba K. Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Science. 282:1998;1705-1708.
253. Taylor C.P., Vartanian M.G., Andruszkiewicz R., Silverman R.B. 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. 11:1992;103-110.
254. Thomas G.M., Frame S., Goedert M., Nathke I., Polakis P., Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and β-catenin. FEBS Lett. 458:1999;247-251.
255. Treiser S., Cascio C., O'Donohue T., Thoa N., Jacobowitz D., Kellar K. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science. 213:1981;1529-1531.
256. Tunnicliff G. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol. 50:1999;347-365.
257. Unlap M.T., Jope R.S. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology. 17:1997;12-17.
258. Vaden D.L., Ding D., Peterson B., Greenberg M.L. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem. 276:2001;15466-15471.
259. Vadnal R., Parthasarathy R. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate. Neuropsychopharmacology. 12:1995;277-285.
260. Van den Berg R.J., Kok P., Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res. 93:1993;279-287.
261. van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem. 32:1979;1769-1780.
262. van der Laan J.W., Jacobs A.W., Bruinvels J. Effects of branched-chain fatty acids on GABA-degradation and behavior: further evidence for a role of GABA in quasi-morphine abstinence behavior. Pharmacol Biochem Behav. 13:1980;843-849.
263. Van Dijken P., Bergsma J.C., Hiemstra H.S., De Vries B., Van Der Kaay J., Van Haastert P.J. Dictyostelium discoideum contains three inositol monophosphatase activities with different substrate specificities and sensitivities to lithium. Biochem J. 314:1996;491-495. Erratum: Biochem J 316, 1007 (1996).
264. VanDongen A.M., VanErp M.G., Voskuyl R.A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia. 27:1986;177-182.
265. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5:1996;245-253.
266. Van Lookeren Campagne M.M., Wang M., Spek W., Peters D., Schaap P. Lithium respecifies cyclic AMP-induced cell-type specific gene expression in Dictyostelium. Dev Genet. 9:1988;589-596.
267. Villeret V., Huang S., Fromm H.J., Lipscomb W.N. Crystallographic evidence for the action of potassium, thallium, and lithium ions on fructose-1,6-bisphosphatase. Proc Natl Acad Sci USA. 92:1995;8916-8920.
268. Vonica A., Weng W., Gumbiner B.M., Venuti J.M. TCF is the nuclear effector of the β-catenin signal that patterns the sea urchin animal-vegetal axis. Dev Biol. 217:2000;230-243.
269. Wang J.F., Bown C.D., Chen B., Young L.T. Identification of mood stabilizer-regulated genes by differential-display PCR. Int J Neuropsychopharmacol. 4:2001;65-74.
270. Watson D.G., Lenox R.H. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem. 67:1996;767-777.
271. Watson D.G., Watterson J.M., Lenox R.H. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther. 285:1998;307-316.
272. Wei H., Qin Z.H., Senatorov V.V., Wei W., Wang Y., Qian Y., Chuang D.M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience. 106:2001;603-612.
273. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., Joyce P.R., Karam E.G., Lee C.K., Lellouch J., Lepine J.P., Newman S.C., Rubio-Stipec M., Wells J.E., Wickramaratne P.J., Wittchen H., Yeh E.K. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 276:1996;293-299.
274. Whittle S.R., Turner A.J. Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem. 31:1978;1453-1459.
275. Wikinski S.I., Acosta G.B., Rubio M.C. Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Gen Pharmacol. 27:1996;635-638.
276. Wikramanayake A.H., Huang L., Klein W.H. β-Catenin is essential for patterning the maternally specified animal-vegetal axis in the sea urchin embryo. Proc Natl Acad Sci USA. 95:1998;9343-9348.
277. Williams R.S., Harwood A.J. Lithium therapy and signal transduction. Trends Pharmacol Sci. 21:2000;61-64.
278. Williams R.S.B., Eames M., Ryves W.J., Viggars J., Harwood A.J. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J. 18:1999;2734-2745.
279. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature. 417:2002;292-295.
280. Woodgett J.R. Judging a protein by more than its name: GSK-3. Sci STKE. 2001:2001;RE12.
281. Yamaguchi Y., Shinagawa A. Marked alteration at midblastula transition in the effect of lithium on formation of the larval body pattern of Xenopus laevis. Dev Growth Differ. 31:1989;531-541.
282. Yamamoto R., Yanagita T., Kobayashi H., Yokoo H., Wada A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J Neurochem. 68:1997;1655-1662.
283. i2 gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem. 276:2001;25742-25752.
284. Yenush L., Belles J.M., Lopez-Coronado J.M., Gil-Mascarell R., Serrano R., Rodriguez P.L. A novel target of lithium therapy. FEBS Lett. 467:2000;321-325.
285. York J.D., Ponder J.W., Chen Z.W., Mathews F.S., Majerus P.W. Crystal structure of inositol polyphosphate 1-phosphatase at 2.3-Å resolution. Biochemistry. 33:1994;13164-13171.
286. York J.D., Ponder J.W., Majerus P.W. Definition of a metal-dependent/Li+-inhibited phoshomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA. 92:1995;5149-5153.
287. York J.D., Guo S., Odom A.R., Spiegelberg B.D., Stolz L.E. An expanded view of inositol signaling. Adv Enzyme Regul. 41:2001;57-71.
288. Yoshida S., Marikawa Y., Satoh N. Regulation of the trunk-tail patterning in the ascidian embryo: a possible interaction of cascades between lithium/β-catenin and localized maternal factor pem. Dev Biol. 202:1998;264-279.
289. Yost C., Farr G.H. 3rd, Pierce S.B., Ferkey D.M., Chen M.M., Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell. 93:1998;1031-1041.
290. Yuan P.X., Chen G., Huang L.D., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res. 58:1998;225-230.
291. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 276:2001;31674-31683.
292. Zhang Y., Iratni R., Erdjument-Bromage H., Tempst P., Reinberg D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell. 89:1997;357-364.
293. Zigova T., Willing A.E., Tedesco E.M., Borlongan C.V., Saporta S., Snable G.L., Sanberg P.R. Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons. Exp Neurol. 157:1999;251-258.